QRxPharma Limited (QRxPharma) is an Australia-based company. The Company is a commercialstage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management. Its product portfolio includes both late and early stage clinical drug candidates. During the fiscal year ended June 30, 2012 (fiscal 2012), the principal activities of the Company consisted of the development and commercialisation of biopharmaceutical products based on largely Australian research, targeting the United States and European markets. In December 2011, the Company entered into collaboration with Actavis Inc. for the commercialisation of immediate release MOXDUO in the United States acute pain market.